Table II.
Characteristics of populations from the included studies – a homogeneity analysis
| Variable | Infliximab | Adalimumab | Golimumab | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACT 1, ACT 2 (Rutgeerts et al. 2005; Sandborn et al. 2009) | Suzuki et al. 2014 | ULTRA 2 (Sandborn et al. 2012; Sandborn et al. 2013; Feagan 2014) | ULTRA 1 (Reinisch et al. 2011; Feagan 2014) | PURSUIT-SC (Sandborn et al. 2014) | PURSUIT-M (Sandborn et al. 2014) | ||||||||||
| IFX 5 mg | PL | ADA 160/80 mg | ADA 80/40 mg | PL | ADA 160/80 mg | PL | ADA 160/80 mg | ADA 80/40 mg | PL | GOL 200/100 mg | PL | GOL 50 mg | GOL 100 mg | PL | |
| Male gender, n (%) | 154 (63.6) | 143 (58.6) | 61 (67.8) | 50 (57.5) | 70 (72.9) | 142 (57.3) | 152 (61.8) | 83 (63.8) | 78 (60.0) | 82 (63.1) | 180 (54.4) | 175 (529) | 89 (57.8) | 77 (50.0) | 75 (48.1) |
| Age, mean ± SD | 41.5 ±13.7 | 40.3 ±13.6 | 42.5 ±14.6 | 44.4 ±15.0 | 41.3 ±13.6 | 39.6 ±12.5 | 41.3 ±13.2 | 41.5 ±16.5 | 43.2 ±16.5 | 41.0 ±15.6 | 40.0 ±13.5 | 39.0 ±13.0 | 39.1 ±13.1 | 41.4 ±13.8 | 40.2 ±14.0 |
| Duration of disease, mean ± SD | 6.3 ±5.4 | 6.4 ±6.3 | 7.8 ±7.1 | 8.3 ±7.7 | 7.8 ±6.6 | 8.1 ±7.1 | 8.5 ±7.4 | 11.7 ±9.9 | 13.4 ±11.4 | 11.3 ±9.8 | 6.4 ±6.2 | 6.0 ±6.6 | 7.2 ±7.0 | 6.8 ±6.9 | 6.9 ±7.0 |
| Mayo score, mean ± SD | 8.4 ±1.6 | 8.5 ±1.6 | 8.6 ±1.4 | 8.5 ±1.4 | 8.5 ±1.6 | 8.9 ±1.5 | 8.9 ±1.8 | 8.8 ±1.6 | 9.0 ±1.6 | 8.7 ±1.6 | 8.6 ±1.5 | 8.3 ±1.5 | 8.5 ±1.3 | 8.1 ±1.4 | 8.3 ±1.4 |
| C-reactive protein (CRP) level, median [mg/dl] | 0.80 | 0.70 | 0.22 | 0.31 | 0.34 | 0.41 | 0.42 | 0.33 | 0.64 | 0.32 | 0.49 | 0.45 | 0.34 | 0.45 | 0.32 |
| Concomitant medication: | |||||||||||||||
| Corticosteroids, n (%) | 130 (53.7)* | 139 (57.0)* | 57 (63.3) | 63 (72.4) | 58 (60.4) | 150 (60.5) | 140 (56.9) | 48 (36.9) | 48 (36.9) | 55 (41.5) | 142 (42.9) | 134 (40.5) | 79 (51.3) | 77 (50.0) | 83 (53.2) |
| Immunomodulators, n (%) | 118 (48.8) | 107 (43.9) | 41 (45.6) | 38 (43.7) | 52 (54.2) | 93 (37.5) | 80 (32.5) | 28 (21.5) | 25 (19.2) | 18 (13.8) | 105 (31.7) | 106 (32.0) | 48 (31.2) | 47 (30.5) | 52 (33.3) |
| Aminosalicylates, n (%) | 174 (71.9) | 174 (71.3) | 83 (92.2)# | 84 (96.6)# | 89 (92.7)# | 146 (58.9) | 155 (63.0) | 105 (80.8) | 99 (76.2) | 98 (75.4) | 270 (81.6) | 276 (83.4) | 119 (77.3) | 128 (83.1) | 125 (80.1) |
*
Patients treated with ≥ 20 mg/day of corticosteroids, IFX – infliximab, ADA – adalimumab, GOL – golimumab, PL – placebo
#
data include patients treated with 5-ASAs.